Find clinical trials for Alzheimer's Disease in New Haven, CT
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Alzheimer's Disease trials near New Haven, CT, USA:
designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...
Phase 2
New Haven, Connecticut, United States and 14 other locations
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's ...
Phase 1
New Haven, Connecticut, United States and 1 other location
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's...
Phase 3
New Haven, Connecticut, United States and 70 other locations
double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's...
Phase 2
Stamford, Connecticut, United States and 31 other locations
efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...
Phase 2, Phase 3
New Haven, Connecticut, United States and 38 other locations
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...
Phase 2, Phase 3
New Haven, Connecticut, United States and 37 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
New Haven, Connecticut, United States and 111 other locations
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...
Phase 2
New Haven, Connecticut, United States and 64 other locations
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elder...
Phase 2
Stamford, Connecticut, United States of America and 63 other locations
versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...
Phase 2
New Haven, Connecticut, United States and 101 other locations
Clinical trials
Research sites
Resources
Legal